Augmented Whole-Body Scanning via Magnifying PET
- PMID: 31899415
- PMCID: PMC7673659
- DOI: 10.1109/TMI.2019.2962623
Augmented Whole-Body Scanning via Magnifying PET
Abstract
A novel technique, called augmented whole-body scanning via magnifying PET (AWSM-PET), that improves the sensitivity and lesion detectability of a PET scanner for whole-body imaging is proposed and evaluated. A Siemens Biograph Vision PET/CT scanner equipped with one or two high-resolution panel-detectors was simulated to study the effectiveness of AWSM-PET technology. The detector panels are located immediately outside the scanner's axial field-of-view (FOV). A detector panel contains 2 ×8 detector modules each consisting of 32 ×64 LSO crystals ( 1.0 ×1.0 ×10.0 mm3 each). A 22Na point source was stepped across the scanner's FOV axially to measure sensitivity profiles at different locations. An elliptical torso phantom containing 7×9 spherical lesions was imaged at different axial locations to mimic a multi-bed-position whole-body imaging protocol. Receiver operating characteristic (ROC) curves were analyzed to evaluate the improvement in lesion detectability by the AWSM-PET technology. Experimental validation was conducted using an existing flat-panel detector integrated with a Siemens Biograph 40 PET/CT scanner to image a torso phantom containing spherical lesions with diameters ranging from 3.3 to 11.4 mm. The contrast-recovery-coefficient (CRC) of the lesions was evaluated for the scanner with or without the AWSM-PET technology. Monte Carlo simulation shows 36%-42% improvement in system sensitivity by a dual-panel AWSM-PET device. The area under the ROC curve is 0.962 by a native scanner for the detection of 4 mm diameter lesions with 5:1 tumor-to-background activity concentration. It was improved to 0.977 and 0.991 with a single- and dual-panel AWSM-PET system, respectively. Experimental studies showed that the average CRC of 3.3 mm and 4.3 mm diameter tumors were improved from 2.8% and 4.2% to 7.9% and 11.0%, respectively, by a single-panel AWSM-PET device. With a high-sensitivity dual-panel device, the corresponding CRC can be further improved to 11.0% and 15.9%, respectively. The principle of the AWSM-PET technology has been developed and validated. Enhanced system sensitivity, CRC and tumor detectability were demonstrated by Monte Carlo simulations and imaging experiments. This technology may offer a cost-effective path to realize high-resolution whole-body PET imaging clinically.
Conflict of interest statement
The authors have no relevant conflicts of interest to disclose.
Figures
References
-
- Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, Oster ZH, Sacker DF, Shiue CY, Turner H, Wan CN, Wolf AP, and Zabinski SV, “A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection,” J Nucl Med, vol. 21, no. 7, pp. 670–5, July, 1980. - PubMed
-
- Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, and Kao CH, “Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis,” European Journal of Radiology, vol. 81, no. 9, pp. 2411–6, September, 2012. - PubMed
-
- Chang MC, Chen JH, Liang JA, Yang KT, Cheng KY, and Kao CH, “Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: a systematic review and meta-analysis,” European Journal of Radiology, vol. 82, no. 2, pp. 366–73, February, 2013. - PubMed
-
- Kakhki VR, Shahriari S, Treglia G, Hasanzadeh M, Zakavi SR, Yousefi Z, Kadkhodayan S, and Sadeghi R, “Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature,” Int J Gynecol Cancer, vol. 23, no. 9, pp. 1536–43, November, 2013. - PubMed
